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Available online 4 January 2017Background and aims: Vascular disease (VD), as assessed by history of myocardial infarction or peripheral artery
disease or aortic plaque, increases stroke risk in atrial fibrillation (AF), and is a component of risk assessment
using the CHA2DS2-VASc score. We investigated if systemic atherosclerosis as detected by ultrasound carotid
plaque (CP) could improve the predictive value of the CHA2DS2-VASc score.
Methods:Weanalysed data from theARAPACIS study, an observational study including 2027 Italian patientswith
non-valvular AF, in whom CP was detected using Doppler Ultrasonography.
Results: VD was reported in 351 (17.3%) patients while CP was detected in 16.6% patients. Adding CP to the VD
definition leaded to higher VD prevalence (30.9%).
During amedian [IQR] follow-up time of 36months, 56 (2.8%) stroke/TIA eventswere recorded. Survival analysis
showed that conventional VD alone did not increase the risk of stroke (Log-Rank: 0.009, p= 0.924), while addi-
tion of CP to conventional VD was significantly associated to an increased risk of stroke (LR: 5.730, p = 0.017).
Cox regression analysis showed that VD + CP was independently associated with stroke (HR: 1.78, 95% CI:
1.05–3.01, p = 0.0318). Reclassification analysis showed that VD + CP allowed a significant risk reclassification
when compared to VD alone in predicting stroke at 36 months (NRI: 0.192, 95% CI: 0.028–0.323, p = 0.032).
Conclusions: In non-valvular AF patients the addition of ultrasound detection of carotid plaque to conventional
VD significantly increases the predictive value of CHA2DS2-VASc score for stroke.







Atrialfibrillation (AF) is themost common sustained arrhythmia en-
countered in clinical practice, accounting for approximately one-third of
all hospitalizations for a cardiac rhythmabnormality [1]. AF is associated
with a fivefold increased risk for stroke, and is estimated to cause 15% of
all strokes [2]. Based on evidence frommany randomized clinical trials,
AF patients are treated with oral anticoagulants such as warfarin or theliclinico 155, Roma 00161, Italy.non-Vitamin K antagonist oral anticoagulants (NOACs) to reduce the
risk of thromboembolic stroke [3].
There is increasing evidence that AF is also associated with systemic
signs of atherosclerosis, such as aortic plaque or low ankle/brachial
index (ABI), which reflects the frequent coexistence of atherosclerotic
risk factors such as hypertension, diabetes mellitus, dyslipidemia and
metabolic syndrome [4,5]. The coexistence of sub-clinical systemic ath-
erosclerosis suggests that clinical events complicatingAFmaybe also at-
tributable to athero-thrombosis in the carotid distribution [6]. Indeed,
“vascular disease” (VD) increases stroke risk in non-valvular AF
(NVAF), and is a component of risk assessment using the CHA2DS2-
VASc score [7]. The usual clinical definition of VD includes a history of
MI or claudication with surgical intervention or the presence of aortic
144 S. Basili et al. / International Journal of Cardiology 231 (2017) 143–149plaque. We argued that diagnosis of aortic plaque may be cumbersome
in clinical practice as it is not a routine analysis and is invasive while ca-
rotid atherosclerosis as assessed by Doppler ultrasound is easier to per-
form, cheaper, not invasive and commonly used to define extra-cranial
atherosclerosis in patients with risk factors.
We therefore hypothesized that inclusion of carotid plaque in the
CHA2DS2-VASc score would better define the prevalence of VD and pos-
sibly improve stroke risk prediction by CHA2DS2-VASc score in the AF
population.We tested this hypothesis in the ARAPACIS study, an obser-
vational study including 2027 Italian patients with NVAF, to investigate
if documentation of carotid plaque, whichwas a predefined assessment




We performed a post-hoc analysis from the “Atrial Fibrillation
Registry for Ankle-brachial Index Prevalence Assessment: Collaborative
Italian Study” (ARAPACIS) which was a prospective nationwide obser-
vational study, conducted by the Italian Society of Internal Medicine
(SIMI), investigating the prevalence of asymptomatic PAD as assessed
by an ankle-brachial index (ABI) ≤0.90, in NVAF patients. This registry
provided information on the prevalence of ABI and its relationship
with classic risk factors of atherosclerosis in AF patients [4]. Further-
more, the study showed that, in NVAF, ABI was useful to discriminate
patients experiencingMI but not stroke [8]. Details about study protocol
and inclusion/exclusion criteria were elsewhere reported [9]. From 1st
October 2010 to 31st October 2012 a total of 2027 patients were en-
rolled and then followed up for three years up to 31st October 2015.
Study protocol was approved for the Coordinator Centre (Sapienza-
University of Rome) with the number 1902/17.06.2010. The study was
subsequently registered at ClinicalTrials.gov (Unique identifier:
NCT01161251). According to the list of enrolling centers reported in
the Appendix A, every institution's Ethics Committee approved the
study protocol.
The study was conducted in accordance with the EU Guidance on
Good Clinical Practice CPMP/ECH/135/95 and the Declaration of Helsin-
ki and its later amendments.
As previously reported [9], all clinical variables of interest and all
data about relevant pharmacological therapies were collected at the
time of enrolment.
Thromboembolic risk was categorized using CHA2DS2-VASc score,
calculated by adding 1 point each for the presence of congestive heart
failure (HF), hypertension, age from 65 to 74 years, diabetes mellitus,
vascular disease (VD) and female sex, and adding 2 points for stroke
or transient ischemic attack (TIA) and age 75 years or older [7]. Conven-
tionally, previous MI or symptomatic PAD or aortic plaque defined VD.
The presence of carotid plaquewas declared in an electronic case re-
port form. The investigator assessed the presence of an atherosclerotic
plaque following the American Society of Echocardiography consensus
statement [10] and carotid plaque (CP) was defined as follows:
1) focal wall thickening that is at least 50% or greater than that of the
surrounding vessel wall or 2) focal region with carotid intima media
thickness N1.5 mm that protrudes into the lumen that is distinct from
the adjacent boundary.
2.2. Assessment of cerebrovascular events (CVEs)
An independent committee (P.F., S. M.L., P.P.E.) adjudicated adverse
events. Occurrence of a CVEwas defined for any ischemic stroke or tran-
sient ischemic attack (TIA) recorded during the follow-up observation.
Ischemic stroke was determined on clinical manifestations and con-
firmed by radiological findings.2.3. Statistical analysis
Continuous variableswere reported asmean±SD, or asmedian and
interquartile range (IQR) as appropriate. Comparisons between groups
of continuous variables were performed by t-test or Mann-Whitney
U test. Categorical variables, reported as counts and percentages, were
compared by Chi-square test or Fisher's exact test, when cell count
was less than five. Kaplan-Meier curves were built for CVEs occurrence.
A Log-Rank test was performed to analyse differences in survival dis-
tributors between subgroups. Univariate and multivariate Cox models
were used to assess clinically relevant variables (age, sex, any anti-
thrombotic therapy, diabetes mellitus, statins, hypertension, heart fail-
ure, previous cardio- or cerebrovascular events, type of AF and
enrolling center) and VD, as well as VD + CP, effects on the incident
endpoint of CVEs. A forward stepwise model selection procedure
based on the AIC was used to select the best multivariate regression
model.
Improvement of VD+ carotid plaque over VD alonewas assessed by
means of continuous Net Reclassification Index (NRI) and median im-
provement in risk scores (MIRS), which were computed as described
by Pencina et al. [11]. The NRI gives roughly the proportion of
misclassified cases that are classified correctly with the new informa-
tion, a NRI of 1 indicates perfect ability to correctly reclassify patients,
and a negative NRI indicates that the new score is worse than its com-
petitor. The NRI was evaluated at 12, 24 and 36months. The Integrated
Discrimination Improvement (IDI) is linked to the discrimination slope.
A positive IDI indicates that a higher discrimination (difference in aver-
age predicted probability for events, comparedwith non-events) for the
VD + carotid plaque over VD alone.
Decision curve analysis (DCA)was computed as described in Vickers
et al. [12]. It shows the estimated number of patients that would opt for
treatment if their risk of an event was above a threshold probability, for
each threshold. DCA can be used to compare predictionmodels with re-
spect to their net benefit.
Time-dependent C-indexeswere estimated bymeans of the Kaplan-
Meier method of Heagerty et al. [13]. Their confidence intervals and
p-values were estimated by means of non-parametric bootstrap.
A two-sided p value b0.05was considered as statistically significant.
All analyses were performed using SPSS v. 22 (IBM, NY, USA) and R v.
3.0.2 (R development core team, Vienna, Austria).3. Results
A detailed description of the overall cohort has been previously re-
ported (9). Briefly, age (mean ± SD) was 73.3 ± 10.0 years with
45.3% (918 patients) females. Of the NVAF types, 842 (41.5%) patients
had paroxysmal AF, 284 (14.0%) were persistent AF and 901 (44.5%)
had permanent AF. Hypertension was the most prevalent risk factor
(82.5%).
According to the conventional VD definition of the CHA2DS2-VASc
score VD was defined as previous MI or symptomatic PAD or aortic
plaque.
VD was reported in 351 (17.3%) patients while CP was detected in
16.6% (n = 336) patients.
Among patients with VD, no significant difference in the occurrence
of CVE was observed between patients with or without stroke (17.3 vs.
17.5%, respectively, p = 0.963) (Fig. 1). Conversely, when the contem-
porary presence of CPwas added to VD, a significant difference between
patients with vs. without CVE was found (30.5% vs. 45.6%, respectively,
p = 0.015) (Fig. 1).
During a median [IQR] follow-up of 36 [22–36] months, 56 CVEs
were reported, with an overall incidence of 1.17 per 100 patient-years.
Patients with CVEs were older (p b 0.001) and with a positive history
for previous stroke/TIA (p b 0.001). They had higher CHA2DS2-VASc
score (p b 0.001) and more prevalent CHA2DS2-VASc score ≥2 (p =
Fig. 1. Proportions of patients with conventional vascular disease (VD) and VD+ ultrasound detection of carotid plaque (CP) according to cerebrovascular events (CVEs) occurrence.
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tients, of borderline statistical significance (p = 0.052) (Table 1).
Conventional VD alone did not differentiate patients with and with-
out CVEs during follow-up (p = 0.963). CP was more prevalent in pa-
tients who experienced stroke/TIA during the follow-up (31.6% vs.
16.1%, p=0.002). Inclusion of CP in the VD definition led to a significant
increase in VD prevalence [30.9%].Table 1






Age, years (median [IQRb]) 74.4 [67.7–80.2] 80.1 [72.5–84.6] b0.001
Female gender, n (%) 885 (44.9) 33 (57.9) 0.052
BMIa, kg/m2 (median [IQR]) 27.2 [24.5–30.5] 26.8 [23.9–30.5] 0.473
Atrial fibrillation type 0.741
Paroxysmal, n (%) 821 (41.7) 21 (36.8)
Persistent, n (%) 276 (14.0) 8 (14.0)
Permanent, n (%) 873 (44.3) 28 (49.2)
Hypertension, n (%) 1627 (82.6) 46 (80.7) 0.711
Hypercholesterolemia, n (%) 754 (38.3) 27 (47.4) 0.164
Smoking habit, n (%) 295 (15.0) 9 (15.8) 0.865
Diabetes, n (%) 454 (23.0) 12 (21.1) 0.724
Heart failure, n (%) 398 (20.2) 14 (24.6) 0.420
Previous stroke/TIAc, n (%) 220 (11.2) 15 (26.3) b0.001
CHA2DS2-VASc (median [IQR]) 3 [2–4] 4 [3–5] b0.001
CHA2DS2-VASc Classes 0.036
Class 0, n (%) 78 (4.0) 1 (1.8)
Class 1, n (%) 236 (12.0) 1 (1.8)
Class ≥2, n (%) 1656 (84.1) 55 (96.5)
Antithrombotic therapy 0.226
None, n (%) 307 (15.6) 9 (15.8)
Antiplatelets, n (%) 381 (19.3) 8 (14.0)
VKAd, n (%) 1190 (60.4) 40 (70.2)
Antiplatelets + VKA, n (%) 92 (4.7) 0 (0.0)
Statins, n (%) 718 (36.4) 18 (31.6) 0.451
ACEe Inhibitors, n (%) 698 (35.4) 17 (29.8) 0.382
ARBs f, n (%) 671 (34.1) 20 (35.1) 0.872
Beta-Blockers, n (%) 799 (40.6) 23 (40.4) 0.975
Calcium Channel Blockers, n (%) 534 (27.1) 17 (29.8) 0.649
a Body Mass Index.
b Inter Quartile range.
c Transient ischemic attack.
d Vitamin K antagonist.
e Angiotensin converting enzyme.
f Angiotensin receptor blockers.3.1. Event-free survival analysis
Conventional VD did not discriminate AF patients who experienced
CVEs during the follow-up (Log-Rank: 0.009, p = 0.924); conversely,
CP presence discriminated patients who experienced stroke/TIA during
the follow-up (Log-Rank: 8.61, p = 0.003). Adding CP to conventional
VD was associated with an enhanced risk of stroke/TIA [Log-Rank:
5.730, p = 0.017, Fig. 2].
On Cox proportional hazards analysis (Table 2), adjusted for gender,
AF type, heart failure, hypertension, statins, previous cardio-vascular
event, enrolling center, any antithrombotic therapy and diabetes,
VD + CP was independently associated with the occurrence of stroke/
TIA during follow-up (p = 0.0318).
3.2. Reclassification analysis, decision curve analysis, and C-statistic
Using NRI, adding CP to VD was significantly better than using con-
ventional VD alone in predicting CVEs at 24 months (p = 0.0399) and
36 months (p = 0.0332). Despite significant reclassification, no signifi-
cant improvement was found according to IDI analysis (Table 3).Fig. 2. Event-free survival for stroke/TIA occurrence according to conventional vascular
disease (VD) + ultrasound detection of carotid plaque (CP). Thick Solid Line = VD+ CP
present; Thick Dashed Line = VD+ CP absent; Log-Rank = 5.730, p = 0.017.
Table 2
Cox regression analysisa for cerebrovascular events [stroke/transient ischemic attack
(TIA)].
HRb 95% CIc p
Previous stroke/TIA 2.41 1.31–4.44 0.0047
Age (per year) 1.07 1.03–1.10 0.0001
Conventional VDd 0.97 0.48–1.94 0.9288
Previous stroke/TIA 2.42 1.32–4.46 0.0044
Age (per year) 1.07 1.03–1.10 0.0003
VD + CPe 1.78 1.05–3.01 0.0318
a Level of entry into the model was set at a p-value = 0.10.
b Adjusted hazard ratio.
c Confidence interval.
d Conventional vascular disease (Myocardial infarction, aortic plaque, symptomatic
peripheral artery disease).
e Ultrasound detection of carotid plaque.
Table 4
C-index for cerebrovascular events (CVEs) occurrence.
C-index 95% CIa p
VDb + CPc at 12 months 0.568 0.498–0.637 0.054
VDb at 12 months 0.557 0.499–0.621 0.068
VDb + CPc at 24 months 0.609 0.561–0.663 b0.001
VDb at 24 months 0.553 0.512–0.596 0.016
VDb + CPc at 36 months 0.626 0.586–0.666 b0.001
VDb at 36 months 0.591 0.555–0.627 b0.001
a Confidence Interval.
b Conventional Vascular Diseases (myocardial infarction, aortic plaque, symptomatic
peripheral artery disease).
c Ultrasound detection of carotid plaque.
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VD and VD+ CP. It shows that with VD alone a net benefit would not
be obtained at all estimable thresholds, while for VD+ CP a rather
steep decision curve is obtained, indicating that VD+ CP is useful
in the decision-making process. VD+ CP had significantly greater
C-statistic (Table 4) than conventional VD alone for CVEs at 24 and
36 months (p b 0.001)
3.3. Sensitivity analysis
To verify the role of VD+ CP in preventing the occurrence of CVEs, a
sensitivity analysis in patients without previous history of stroke/TIA
was performed. The analysis showed that in AF patients without a pre-
vious history of stroke/TIA VD+CP could identify patients at higher risk
for CVEs occurrence (Log-Rank: 5.787, p = 0.016).
4. Discussion
In the present study, inclusion of ultrasound detection of carotid
plaque in the diagnosis of VD increased the predictive values of
CHA2DS2-VASc score; this reinforces the concept that systemic athero-
sclerosis is anothermechanism accounting for ischemic stroke in AF [6].
Previous study by ARAPACIS registry demonstrated AF is associated
with atherosclerosis of extracranial carotid arteries, as assessed by ca-
rotid IMT, but its impact with cerebrovascular disease was not investi-
gated [14]. The present analysis of the ARAPACIS registry supports and
extends these finding by demonstrating that carotid plaque is detect-
able in approximately 17% of AF. Furthermore, during the follow-up, pa-
tientswith CPwere at higher risk of experiencing acute cerebral disease,
thereby suggesting that atherosclerosis of carotid artery might also be
implicated in cerebral ischemia.
VDhas been included in the CHA2DS2-VASc score to improve its abil-
ity to predict stroke in AF patients [7]. To further address the role of VD
in predicting stroke the ARAPACIS registry investigated two markers of
systemic atherosclerosis, namely ABI and CP, to assess their predictive
values versus cerebral and coronary heart disease in AF population.
While we found that ABI is able to predict coronary heart disease [8],
the present study shows that ultrasound detection of carotid plaqueTable 3
Reclassification analysis for cerebrovascular events (CVEs) occurrence.
NRIa 95% CIb
VDd + CPe vs. VDd at 12 months 0.186 −0.058–0.396
VDd + CPe vs. VDd at 24 months 0.193 0.010–0.353
VDd + CPe vs. VDd at 36 months 0.192 0.028–0.323
a Net reclassification improvement.
b Confidence interval.
c Integrated discrimination improvement.
d Conventional vascular diseases (myocardial infarction, aortic plaque, symptomatic periphe
e Ultrasound detection of carotid plaque.was more able to predict ischemic cerebro-vascular disease. Thus, CP
had more frequently detected in AF experiencing CVEs compared to
those without CP and independently predicted CVEs after adjusting
for confounding variables. Analysis of CP greatly increased the preva-
lence of VD, which was 17% by conventional definition and 30% by
adding CP to conventional VD definition. Then, by including CP in the
VD definition, this also improved the predictive value of VD for
predicting stroke/TIA compared to conventional VD definition, suggest-
ing that ultrasound detection of carotid plaque may be useful to stratify
patients at risk of stroke/TIA in the AF population.
We provide further support to the inclusion of VD as a variable
predicting ischemic cerebro-vascular disease in AF population and sug-
gest that CP improves the performance of the CHA2DS2-VASc score. This
finding supports and extends a previous study reporting that inclusion
of carotid plaque in the CHA2DS2-VASc score improves its predictive
value in anAF population not on treatmentwithwarfarin [15]. Ourfind-
ing reinforces also the concept that in AF population ischemic stroke is
not only of thrombo-embolic but also of athero-thrombotic origin.
This suggestion has therapeutic implications as it implies that non-
valvular AF could benefit not only from oral anticoagulants but also pos-
sibly from anti-atherosclerotic drugs [16]. Thus, further study is needed
to see if adding anti-atherosclerotic drugs such statins, which also pos-
sess anti-thrombotic properties [16], in addition to oral anticoagulants
may be of benefit in further reducing the risk of CVEs in AF population.
4.1. Study limitations
The results are limited by: 1) retrospective analysis of an observa-
tional cohort, 2) relatively small ischemic cerebrovascular events. Fur-
thermore, analysis of CP was not centralized and, therefore, diagnosis
was performed by each single center. However, the analysis should
not be biased as each operator followed the AHA definition of CP and
data were collected immediately after patient's inclusion. Around 70%
of patients in our cohort were taking oral anticoagulant therapy; never-
theless, we had no information on the quality of oral anticoagulation for
all participants.
Furthermore, most of our findings are based on NRI, which has lim-
itations. In a simulation study, Pepe et al. [17] showed that with large
data sets one might obtain a positive NRI even for a clinically irrelevant
biomarker, for instance. We speculate that this situation might notp IDIc 95% CIb p
0.1462 0.001 −0.000–0.005 0.2259
0.0399 0.003 −0.001–0.010 0.1262
0.0332 0.005 −0.000–0.014 0.0997
ral artery disease).
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in Pepe's simulations. Additionally, in the simulations by Pepe et al. [17]
a negative difference in C-indexwas always obtained,while in our study
we observed a small but positive increase. It is well known that puta-
tively relevant biomarkers might lead to tiny and non-significant in-
creases in C-indexes; thus, we consider the small increase in C-index
simply as a confirmation that the positive NRI is not an artefact.
5. Conclusions
In non-valvular AF patients the addition of CP to conventional VD in-
creases the predictive value of CHA2DS2-VASc score for stroke. Hence,
analysis of CP could be included in the routine assessment of
CHA2DS2-VASc score in AF patients.
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